In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: St. John's wort

This article was originally published in The Tan Sheet

Executive Summary

St. John's wort: NIH Office of Alternative Medicine and National Institute of Mental Health will issue a request for proposals in late May for a clinical trial to examine the safety and efficacy of treating mild to moderate depression with the herb Hypericum perforatum, or St. John's wort ("The Tan Sheet" Sept. 23, 1996, p. 7). The herb is commonly used in Europe as a treatment for depression. A meta-analysis of 23 trials conducted by German researchers that appeared in the Aug. 3 issue of the British Medical Journal concludes that the herb is superior to placebo for treating mild to moderate depression, although the study points out that an optimum dosage level or form is yet to be determined ("The Tan Sheet" Aug. 5, 1996, p. 16)...
Advertisement
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS087036

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel